Elevated Capital Advisors LLC Has $1.38 Million Stock Holdings in AbbVie Inc. $ABBV

Elevated Capital Advisors LLC decreased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 33.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,335 shares of the company’s stock after selling 3,139 shares during the period. Elevated Capital Advisors LLC’s holdings in AbbVie were worth $1,378,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Chelsea Counsel Co. acquired a new position in shares of AbbVie in the 3rd quarter worth approximately $26,000. Litman Gregory Wealth Management LLC acquired a new stake in AbbVie in the 4th quarter valued at $28,000. Westend Capital Management LLC bought a new stake in AbbVie in the fourth quarter valued at $29,000. Imprint Wealth LLC grew its position in AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after acquiring an additional 45 shares during the period. Finally, Texas Capital Bancshares Inc TX acquired a new position in AbbVie during the third quarter worth $31,000. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Stock Performance

Shares of ABBV stock opened at $249.98 on Friday. The stock’s fifty day moving average is $224.54 and its 200-day moving average is $221.06. The stock has a market capitalization of $441.67 billion, a PE ratio of 123.14, a PEG ratio of 0.83 and a beta of 0.30. AbbVie Inc. has a 52 week low of $184.63 and a 52 week high of $261.64.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period in the previous year, the business posted $2.46 earnings per share. As a group, analysts forecast that AbbVie Inc. will post 14.25 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. AbbVie’s payout ratio is currently 340.89%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ABBV. JPMorgan Chase & Co. lifted their price objective on AbbVie from $260.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday. Wells Fargo & Company set a $260.00 target price on shares of AbbVie in a report on Monday, June 22nd. Bank of America upgraded shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 target price for the company in a research report on Thursday, April 30th. Guggenheim lifted their price target on shares of AbbVie from $249.00 to $261.00 and gave the company a “buy” rating in a report on Thursday. Finally, Cantor Fitzgerald boosted their price target on shares of AbbVie from $240.00 to $265.00 and gave the company an “overweight” rating in a research report on Monday. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, AbbVie has an average rating of “Moderate Buy” and an average price target of $258.19.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: JPMorgan raised its price target on AbbVie to $280 from $260 and kept an overweight rating, signaling confidence in further upside. Benzinga
• Positive Sentiment: The European Commission approved AbbVie’s Tepkinly-based combination for relapsed or refractory follicular lymphoma, expanding the company’s oncology footprint and potentially supporting future sales growth. Pharmaceutical Technology
• Positive Sentiment: AbbVie also completed a first-in-human ABBV-277 trial, and early safety data could matter for its pipeline if the program continues to show promise. TipRanks
• Neutral Sentiment: West Pharmaceutical completed the SmartDose 3.5mL sale to AbbVie, a transaction that helps West refocus on its core business but is not likely to be a major direct driver for AbbVie’s stock. Zacks
• Neutral Sentiment: Market commentary on cystic fibrosis drug development highlighted AbbVie’s presence in a growing orphan-drug category, but the article was broad industry context rather than a company-specific catalyst. Yahoo Finance
• Negative Sentiment: Despite the positive headlines, AbbVie’s shares ended the session lower, suggesting investors may be taking profits or waiting for the upcoming earnings report and clearer pipeline results. Zacks

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.